Immatics (NASDAQ:IMTX) Issues Earnings Results

Immatics (NASDAQ:IMTX) posted its earnings results on Thursday. The company reported $0.48 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.51, Zacks reports. Immatics had a negative return on equity of 15.90% and a negative net margin of 47.94%. The company had revenue of $15.67 million for the quarter, compared to the consensus estimate of $16.16 million.

Immatics Stock Performance

Shares of NASDAQ IMTX traded down $0.08 during midday trading on Friday, reaching $4.63. The company’s stock had a trading volume of 574,228 shares, compared to its average volume of 625,304. The company has a market cap of $552.62 million, a P/E ratio of -7.02 and a beta of 0.83. The business’s 50 day moving average price is $4.97 and its two-hundred day moving average price is $7.54. Immatics has a fifty-two week low of $4.06 and a fifty-two week high of $13.77.

Hedge Funds Weigh In On Immatics

A hedge fund recently raised its stake in Immatics stock. Bank of America Corp DE boosted its position in shares of Immatics (NASDAQ:IMTX) by 166.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,575 shares of the company’s stock after buying an additional 2,231 shares during the period. Bank of America Corp DE’s holdings in Immatics were worth $25,000 at the end of the most recent quarter. Institutional investors and hedge funds own 64.41% of the company’s stock.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.